From: MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer
Parameters | Recurrent group (n = 24) | Nonrecurrent group (n = 54) | P value |
---|---|---|---|
Age (year) | 44.9 ± 22.5 | 46.2 ± 18.9 | 0.792 |
Sex | |||
Male | 5(%) | 13(%) | 0.754 |
Female | 19(%) | 41(%) | |
ASA physical status | |||
I | 8(%) | 20(%) | 0.673 |
II | 11(%) | 27(%) | |
III | 5(%) | 7(%) | |
BMI (kg/m2) | 21.4 ± 4.3 | 20.7 ± 3.8 | 0.473 |
ATA risk | |||
Low | 6 | 28 | 0.030* |
Intermediate | 14 | 24 | |
High | 4 | 2 | |
MSKCC–NY risk | |||
Low | 4 | 11 | 0.017* |
Intermediate | 10 | 36 | |
High | 10 | 7 | |
Primary tumor size (mm) | 29.4 ± 5.4 | 22.3 ± 4.8 | <0.001* |
Lymph node dissection | 15(62.5%) | 37(68.5%) | 0.603 |
RAI postoperatively | 6(25.0%) | 22(40.7%) | 0.181 |
Recurrence place | |||
Locoregional | 22(%) | 47(%) | |
Distant metastasis | 2(%) | 7(%) | 0.713 |
Serum thyroglobulin (ng/mL) | 1.6 ± 1.4 | 1.0 ± 1.3 | 0.071 |
TNM stage | |||
I–II | 13 | 43 | 0.021* |
III–IV | 11 | 11 | |
Extrathyroid extension | |||
Yes | 15 | 17 | 0.010* |
No | 9 | 37 | |
Vascular invasion | |||
Yes | 11 | 18 | 0.292 |
No | 13 | 36 | |
Perineural invasion | |||
Yes | 6 | 7 | 0.188 |
No | 18 | 47 | |
Cervical lymph node metastasis | |||
Yes | 7 | 6 | 0.048* |
No | 17 | 48 | |
Histological subtype | |||
Classic | 19 | 42 | 0.891 |
Follicular | 5 | 12 | |
Multifocal tumors | |||
Yes | 13 | 19 | 0.116 |
No | 11 | 35 | |
Bilateral tumors | |||
Yes | 7 | 16 | 0.967 |
No | 17 | 38 |